{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:41:48Z","timestamp":1792687308325,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974308"],"award-info":[{"award-number":["81974308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary cutaneous amyloidosis (PCA) lacks consensus-based therapeutic guidelines, with conventional modalities demonstrating suboptimal clinical responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the efficacy and safety profile of oral tofacitinib, a Janus kinase 1\/3 inhibitor, in PCA management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-centre, open-label, single-arm prospective interventional study enrolled 20 patients with PCA receiving tofacitinib 5\u2005mg twice daily. Demographic parameters, disease characteristics [measured using the pruritus numeric rating scale (p-NRS), Dermatology Life Quality Index (DLQI) and Lesion Severity (LS) scores], and adverse events were systematically recorded at baseline and weeks 2, 6 and 10 post-treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 10, significant reductions were observed across all endpoints: p-NRS from 6.9 (SD 2.9) to 0.4 (SD 0.6, P &amp;lt; 0.001); DLQI from 11.8 (SD 5.6) to 2.6 (SD 2.5, P &amp;lt; 0.001); and LS from 13.3 (SD 5.2) to 4.9 (SD 2.4, P &amp;lt; 0.001). Patients with lichen amyloidosis (8 of 15) and biphasic amyloidosis (3 of 3), but neither of the 2 patients with macular amyloidosis, achieved the primary efficacy threshold. Two treatment-emergent adverse events occurred; these were transient hepatobiliary enzyme elevations resolving with hepatoprotectants and one patient with a self-limiting upper respiratory infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tofacitinib demonstrates rapid antipruritic effects and sustained lesion clearance in PCA, with favourable tolerability. Study limitations, including the small sample size (n = 20), 10-week duration and uncontrolled design, which may limit generalizability, warrant phase III trials for validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf364","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T11:49:11Z","timestamp":1754567351000},"page":"86-91","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of primary cutaneous amyloidosis with tofacitinib: preliminary observations from a single-arm clinical trial"],"prefix":"10.1093","volume":"51","author":[{"given":"Pan","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Baiyun District People's Hospital , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhongnan Hospital of Wuhan University , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"2025122312170222000_llaf364-B1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40257-017-0278-9","article-title":"Primary localized cutaneous amyloidosis: a systematic treatment review","volume":"18","author":"Weidner","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2025122312170222000_llaf364-B2","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1111\/ajd.14012","article-title":"Primary cutaneous amyloidosis: a review of the available studies and gaps in data","volume":"64","author":"Aung","year":"2023","journal-title":"Australas J Dermatol"},{"key":"2025122312170222000_llaf364-B3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4103\/IJPM.IJPM_32_20","article-title":"Primary cutaneous amyloidosis: a clinicopathological, histochemical, and immunohistochemical study","volume":"64","author":"Sinha","year":"2021","journal-title":"Indian J Pathol Microbiol"},{"key":"2025122312170222000_llaf364-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/DAD.0b013e31823465c7","article-title":"Cutaneous amyloidosis: a concept review","volume":"34","author":"Fernandez-Flores","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"2025122312170222000_llaf364-B5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2133.1999.02651.x","article-title":"Apoptosis in primary cutaneous amyloidosis","volume":"140","author":"Chang","year":"1999","journal-title":"Br J Dermatol"},{"key":"2025122312170222000_llaf364-B6","doi-asserted-by":"crossref","first-page":"653724","DOI":"10.1155\/2014\/653724","article-title":"A novel missense mutation in oncostatin M receptor beta causing primary localized cutaneous amyloidosis","volume":"2014","author":"Saeedi","year":"2014","journal-title":"BioMed Res Int"},{"key":"2025122312170222000_llaf364-B7","first-page":"545","article-title":"Friction melanosis, friction amyloidosis, macular amyloidosis, towel melanosis: many names for the same clinical entity","volume":"11","author":"Siragusa","year":"2001","journal-title":"Eur J Dermatol"},{"key":"2025122312170222000_llaf364-B8","doi-asserted-by":"crossref","first-page":"e0120623","DOI":"10.1371\/journal.pone.0120623","article-title":"Health-related quality of life in patients with primary cutaneous amyloidosis","volume":"10","author":"Fang","year":"2015","journal-title":"PLOS ONE"},{"key":"2025122312170222000_llaf364-B9","first-page":"13030","article-title":"Clinical resolution of generalized lichen amyloidosis with dupilumab: a new alternative therapy","volume":"26","author":"Humeda","year":"2020","journal-title":"Dermatol Online J"},{"key":"2025122312170222000_llaf364-B10","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.12998\/wjcc.v11.i11.2549","article-title":"Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: four case reports","volume":"11","author":"Zhu","year":"2023","journal-title":"World J Clin Cases"},{"key":"2025122312170222000_llaf364-B11","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1111\/jdv.18756","article-title":"Upadacitinib for treatment-resistant lichen amyloidosis","volume":"37","author":"Solimani","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122312170222000_llaf364-B12","doi-asserted-by":"crossref","first-page":"e15724","DOI":"10.1111\/dth.15724","article-title":"Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib","volume":"35","author":"Xia","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025122312170222000_llaf364-B13","doi-asserted-by":"crossref","first-page":"e15312","DOI":"10.1111\/dth.15312","article-title":"Tofacitinib for the treatment of primary cutaneous amyloidosis: a case report","volume":"35","author":"Chen","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025122312170222000_llaf364-B14","doi-asserted-by":"crossref","first-page":"1477664","DOI":"10.3389\/fimmu.2024.1477664","article-title":"Case report: abrocitinib: a potential therapeutic option for lichen amyloidosis associated with atopic dermatitis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"2025122312170222000_llaf364-B15","doi-asserted-by":"crossref","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"2025122312170222000_llaf364-B16","doi-asserted-by":"crossref","first-page":"111029","DOI":"10.1016\/j.intimp.2023.111029","article-title":"Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment","volume":"124","author":"Shih","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025122312170222000_llaf364-B17","doi-asserted-by":"crossref","first-page":"790125","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"2025122312170222000_llaf364-B18","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/jocd.16356","article-title":"Safety and efficacy of tofacitinib in 97 alopecia areata patients","volume":"23","author":"Nasimi","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"2025122312170222000_llaf364-B19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025122312170222000_llaf364-B20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2025122312170222000_llaf364-B21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.anl.2013.04.009","article-title":"Keratinic amyloidosis of the external auditory canal","volume":"41","author":"Wasano","year":"2014","journal-title":"Auris Nasus Larynx"},{"key":"2025122312170222000_llaf364-B22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ajhg.2007.09.002","article-title":"Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis","volume":"82","author":"Arita","year":"2008","journal-title":"Am J Hum Genet"},{"key":"2025122312170222000_llaf364-B23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/lsm.23313","article-title":"Fractional carbon dioxide laser is effective in amelioration of pruritus in primary cutaneous amyloidosis: a clinical and biochemical study","volume":"53","author":"Fawzi","year":"2021","journal-title":"Lasers Surgery Med"},{"key":"2025122312170222000_llaf364-B24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2340\/00015555-1829","article-title":"A Th2 cytokine interleukin-31 signature in a case of sporadic lichen amyloidosis","volume":"95","author":"Dousset","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2025122312170222000_llaf364-B25","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1111\/jdv.20039","article-title":"Primary localized cutaneous amyloidosis associated with atopic dermatitis treated successfully with nemolizumab","volume":"38","author":"Fukumoto","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122312170222000_llaf364-B26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2025122312170222000_llaf364-B27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-\u00adexpressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2025122312170222000_llaf364-B28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/09546630252775180","article-title":"Lack of effect of dimethylsulphoxide in cutaneous amyloidosis","volume":"13","author":"Pandhi","year":"2002","journal-title":"J Dermatolog Treat"},{"key":"2025122312170222000_llaf364-B29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/09546634.2019.1655136","article-title":"The therapeutic effects of 1540-nm nonablative fractional erbium laser on macular amyloidosis: a randomized clinical trial","volume":"32","author":"Nahidi","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2025122312170222000_llaf364-B30","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10103-020-02954-y","article-title":"A comparative study of the efficacy of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy alone and in combination with erbium:YAG laser therapy: tracing and objective measurement of melanin index in macular amyloidosis","volume":"35","author":"Nilforoushzadeh","year":"2020","journal-title":"Lasers Med Sci"},{"key":"2025122312170222000_llaf364-B31","doi-asserted-by":"crossref","first-page":"e13305","DOI":"10.1111\/dth.13305","article-title":"Efficacy of topical dimethyl sulfoxide (DMSO) 50% solution vs. tretinoin 0.5% cream in treatment of patients with primary macular amyloidosis: a split-side single-blinded randomized clinical trial","volume":"33","author":"Saki","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025122312170222000_llaf364-B32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1346-8138.2010.01081.x","article-title":"Transcutaneous electrical nerve stimulation for reduction of pruritus in macular amyloidosis and lichen simplex","volume":"38","author":"Y\u00fcksek","year":"2011","journal-title":"J Dermatol"},{"key":"2025122312170222000_llaf364-B33","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/jocd.16180","article-title":"Efficacy of topical gabapentin in women with primary macular amyloidosis: a side-\u00adby-side triple-blinded randomized clinical trial","volume":"23","author":"Abtahi-Naeini","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"2025122312170222000_llaf364-B34","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1111\/jocd.16517","article-title":"The effect of topical tranexamic acid with micro-needling and micro-needling alone in treatment of macular amyloidosis","volume":"23","author":"Gheisari","year":"2024","journal-title":"J\u00a0Cosmet Dermatol"},{"key":"2025122312170222000_llaf364-B35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10103-023-03965-1","article-title":"Evaluation and comparison of Q-switched Nd:YAG laser 1064\u2005nm and Er:YAG laser 2940\u2005nm in the treatment of macular amyloidosis","volume":"39","author":"Mokhtari","year":"2024","journal-title":"Lasers Med Sci"},{"key":"2025122312170222000_llaf364-B36","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/lsm.22361","article-title":"Efficacy of different modes of fractional CO2 laser in the treatment of primary cutaneous amyloidosis: a randomized clinical trial","volume":"47","author":"Esmat","year":"2015","journal-title":"Lasers Surg Med"},{"key":"2025122312170222000_llaf364-B37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/ajd.14198","article-title":"The efficacy of topical 0.025% capsaicin gel for the treatment of lichen amyloidosis: a pilot study","volume":"65","author":"Tanabodee","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2025122312170222000_llaf364-B38","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1111\/ijd.16698","article-title":"Treatment of primary cutaneous lichenoid amyloidosis with abrocitinib: a pilot study in two cases","volume":"62","author":"Bai","year":"2023","journal-title":"Int J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf364\/63979996\/llaf364.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/1\/86\/63979996\/llaf364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/1\/86\/63979996\/llaf364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:17:10Z","timestamp":1766510230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/1\/86\/8226010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf364","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,8,7]]}}}